Biotechnology
In 2021, Pfizer sold a drug candidate for $10 million upfront. This week, that same drug delivered a Phase 3 win that could reshape the treatment of the most common form of breast cancer and generate more than $2 billion in annual sales.
Biotechnology
UCB's $2.2 billion acquisition of Candid Therapeutics signals a fundamental shift in autoimmune treatment strategy. T-cell engagers could reshape immunology the way CAR-T transformed oncology.
Policy
The FDA has launched proof-of-concept real-time clinical trials with AstraZeneca and Amgen, signaling a fundamental shift in how drug development data is monitored and regulatory decisions are made.
Pharmaceuticals
Teva Pharmaceutical Industries' $700 million acquisition of Emalex Biosciences brings ecopipam, a first-in-class D1 receptor antagonist, to pediatric Tourette syndrome treatment—challenging decades of dopamine D2-targeting therapy.
Pharmaceuticals
Sun Pharmaceutical's $11.75 billion acquisition of Organon marks a watershed moment in global pharmaceutical consolidation. The deal reveals how Indian drugmakers are evolving from generics suppliers into genuine global players, while exposing the structural pressures reshaping the industry.
Biotechnology
Intellia Therapeutics announced positive Phase 3 results from the HAELO trial, marking the first time a Phase 3 clinical trial of an in vivo CRISPR-based gene editing therapy has reported positive outcomes.
Biotechnology
On April 23, 2026, the FDA granted accelerated approval to Regeneron's Otarmeni, the first gene therapy ever approved for genetic hearing loss—a breakthrough that represents a categorical shift in what medicine can do.
Biotechnology
Kyverna Therapeutics presented groundbreaking KYSA-8 trial data showing that a single CAR-T cell infusion could achieve what years of immunosuppression cannot: a durable immune reset in stiff person syndrome patients, potentially opening an entirely new therapeutic category for autoimmune diseases.
Biotechnology
Regeneron's Phase 3 NIMBLE trial data for cemdisiran demonstrates a paradigm shift in myasthenia gravis treatment. A quarterly subcutaneous injection achieves meaningful clinical outcomes with a favorable safety profile, potentially redefining patient care in this chronic neuromuscular disorder.
Policy
Trump's executive order fast-tracking FDA review of psychedelic drugs like psilocybin and ibogaine signals a major shift for mental health treatment and the biotech sector.
New pharmacokinetic data shows D-PLEX₁₀₀ delivers 30 days of infection protection using a fraction of the antibiotics used to treat infections today, with minimal to no impact on the rest of the body Think about the last time you were prescribed antibiotics for something routine, like a common bacterial infection.
Biotechnology
Kailera Therapeutics' record-breaking $625 million IPO marks a pivotal moment in the obesity drug market, signaling investor confidence in Chinese-origin drug pipelines and validating a new model for biotech fundraising.